Mechanisms Underlying Potential Therapeutic Approaches for COVID-19.
Identifieur interne : 000B26 ( Main/Exploration ); précédent : 000B25; suivant : 000B27Mechanisms Underlying Potential Therapeutic Approaches for COVID-19.
Auteurs : Abdelouaheb Benani [Maroc] ; Sanae Ben Mkaddem [France]Source :
- Frontiers in immunology [ 1664-3224 ] ; 2020.
Descripteurs français
- KwdFr :
- Anti-inflammatoires (usage thérapeutique), Anticoagulants (usage thérapeutique), Anticorps antiviraux (usage thérapeutique), Antiviraux (usage thérapeutique), Betacoronavirus (effets des médicaments et des substances chimiques), Betacoronavirus (immunologie), Humains (MeSH), Infections à coronavirus (prévention et contrôle), Infections à coronavirus (traitement médicamenteux), Infections à coronavirus (transmission), Insuffisance respiratoire (thérapie), Pandémies (prévention et contrôle), Pneumopathie virale (prévention et contrôle), Pneumopathie virale (traitement médicamenteux), Pneumopathie virale (transmission), Quarantaine (méthodes).
- MESH :
- effets des médicaments et des substances chimiques : Betacoronavirus.
- immunologie : Betacoronavirus.
- méthodes : Quarantaine.
- prévention et contrôle : Infections à coronavirus, Pandémies, Pneumopathie virale.
- thérapie : Insuffisance respiratoire.
- traitement médicamenteux : Infections à coronavirus, Pneumopathie virale.
- usage thérapeutique : Anti-inflammatoires, Anticoagulants, Anticorps antiviraux, Antiviraux, Infections à coronavirus, Pneumopathie virale.
- Humains.
English descriptors
- KwdEn :
- Anti-Inflammatory Agents (therapeutic use), Antibodies, Viral (therapeutic use), Anticoagulants (therapeutic use), Antiviral Agents (therapeutic use), Betacoronavirus (drug effects), Betacoronavirus (immunology), Coronavirus Infections (drug therapy), Coronavirus Infections (prevention & control), Coronavirus Infections (transmission), Cytokine Release Syndrome (drug therapy), Humans (MeSH), Pandemics (prevention & control), Pneumonia, Viral (drug therapy), Pneumonia, Viral (prevention & control), Pneumonia, Viral (transmission), Quarantine (methods), Respiratory Insufficiency (therapy).
- MESH :
- chemical , therapeutic use : Anti-Inflammatory Agents, Antibodies, Viral, Anticoagulants, Antiviral Agents.
- drug effects : Betacoronavirus.
- drug therapy : Coronavirus Infections, Cytokine Release Syndrome, Pneumonia, Viral.
- immunology : Betacoronavirus.
- methods : Quarantine.
- prevention & control : Coronavirus Infections, Pandemics, Pneumonia, Viral.
- therapy : Respiratory Insufficiency.
- transmission : Coronavirus Infections, Pneumonia, Viral.
- Humans.
Abstract
Coronavirus disease (COVID-19) is caused by severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2), which is a betacoronavirus, and is associated with cytokine storm inflammation and lung injury, leading to respiratory distress. The transmission of the virus is mediated by human contact. To control and prevent the spread of this virus, the majority of people worldwide are facing quarantine; patients are being subjected to non-specific treatments under isolation. To prevent and stop the COVID-19 pandemic, several clinical trials are in the pipeline. The current clinical trials either target the intracellular replication and spread of the virus or the cytokine storm inflammation seen in COVID-19 cases during the later stages of the disease. Since both targeting strategies are different, the window drug administration plays a crucial role in the efficacy of the treatment. Here, we review the mechanism underlying SARS-CoV-2 cell infection and potential future therapeutic approaches.
DOI: 10.3389/fimmu.2020.01841
PubMed: 32793246
PubMed Central: PMC7385230
Affiliations:
Links toward previous steps (curation, corpus...)
Le document en format XML
<record><TEI><teiHeader><fileDesc><titleStmt><title xml:lang="en">Mechanisms Underlying Potential Therapeutic Approaches for COVID-19.</title><author><name sortKey="Benani, Abdelouaheb" sort="Benani, Abdelouaheb" uniqKey="Benani A" first="Abdelouaheb" last="Benani">Abdelouaheb Benani</name><affiliation wicri:level="1"><nlm:affiliation>Unité de Biologie Moléculaire, Institut Pasteur du Maroc, Casablanca, Morocco.</nlm:affiliation><country xml:lang="fr">Maroc</country><wicri:regionArea>Unité de Biologie Moléculaire, Institut Pasteur du Maroc, Casablanca</wicri:regionArea><wicri:noRegion>Casablanca</wicri:noRegion></affiliation></author><author><name sortKey="Ben Mkaddem, Sanae" sort="Ben Mkaddem, Sanae" uniqKey="Ben Mkaddem S" first="Sanae" last="Ben Mkaddem">Sanae Ben Mkaddem</name><affiliation wicri:level="3"><nlm:affiliation>U978 Institut National de la Santé et de la Recherche Médicale, Bobigny, France.</nlm:affiliation><country xml:lang="fr">France</country><wicri:regionArea>U978 Institut National de la Santé et de la Recherche Médicale, Bobigny</wicri:regionArea><placeName><region type="region">Île-de-France</region><region type="old region">Île-de-France</region><settlement type="city">Bobigny</settlement></placeName></affiliation><affiliation wicri:level="3"><nlm:affiliation>UFR SMBH, Université Sorbonne Paris Nord, Bobigny, France.</nlm:affiliation><country xml:lang="fr">France</country><wicri:regionArea>UFR SMBH, Université Sorbonne Paris Nord, Bobigny</wicri:regionArea><placeName><region type="region">Île-de-France</region><region type="old region">Île-de-France</region><settlement type="city">Bobigny</settlement></placeName></affiliation></author></titleStmt><publicationStmt><idno type="wicri:source">PubMed</idno><date when="2020">2020</date><idno type="RBID">pubmed:32793246</idno><idno type="pmid">32793246</idno><idno type="doi">10.3389/fimmu.2020.01841</idno><idno type="pmc">PMC7385230</idno><idno type="wicri:Area/Main/Corpus">000609</idno><idno type="wicri:explorRef" wicri:stream="Main" wicri:step="Corpus" wicri:corpus="PubMed">000609</idno><idno type="wicri:Area/Main/Curation">000609</idno><idno type="wicri:explorRef" wicri:stream="Main" wicri:step="Curation">000609</idno><idno type="wicri:Area/Main/Exploration">000609</idno></publicationStmt><sourceDesc><biblStruct><analytic><title xml:lang="en">Mechanisms Underlying Potential Therapeutic Approaches for COVID-19.</title><author><name sortKey="Benani, Abdelouaheb" sort="Benani, Abdelouaheb" uniqKey="Benani A" first="Abdelouaheb" last="Benani">Abdelouaheb Benani</name><affiliation wicri:level="1"><nlm:affiliation>Unité de Biologie Moléculaire, Institut Pasteur du Maroc, Casablanca, Morocco.</nlm:affiliation><country xml:lang="fr">Maroc</country><wicri:regionArea>Unité de Biologie Moléculaire, Institut Pasteur du Maroc, Casablanca</wicri:regionArea><wicri:noRegion>Casablanca</wicri:noRegion></affiliation></author><author><name sortKey="Ben Mkaddem, Sanae" sort="Ben Mkaddem, Sanae" uniqKey="Ben Mkaddem S" first="Sanae" last="Ben Mkaddem">Sanae Ben Mkaddem</name><affiliation wicri:level="3"><nlm:affiliation>U978 Institut National de la Santé et de la Recherche Médicale, Bobigny, France.</nlm:affiliation><country xml:lang="fr">France</country><wicri:regionArea>U978 Institut National de la Santé et de la Recherche Médicale, Bobigny</wicri:regionArea><placeName><region type="region">Île-de-France</region><region type="old region">Île-de-France</region><settlement type="city">Bobigny</settlement></placeName></affiliation><affiliation wicri:level="3"><nlm:affiliation>UFR SMBH, Université Sorbonne Paris Nord, Bobigny, France.</nlm:affiliation><country xml:lang="fr">France</country><wicri:regionArea>UFR SMBH, Université Sorbonne Paris Nord, Bobigny</wicri:regionArea><placeName><region type="region">Île-de-France</region><region type="old region">Île-de-France</region><settlement type="city">Bobigny</settlement></placeName></affiliation></author></analytic><series><title level="j">Frontiers in immunology</title><idno type="eISSN">1664-3224</idno><imprint><date when="2020" type="published">2020</date></imprint></series></biblStruct></sourceDesc></fileDesc><profileDesc><textClass><keywords scheme="KwdEn" xml:lang="en"><term>Anti-Inflammatory Agents (therapeutic use)</term><term>Antibodies, Viral (therapeutic use)</term><term>Anticoagulants (therapeutic use)</term><term>Antiviral Agents (therapeutic use)</term><term>Betacoronavirus (drug effects)</term><term>Betacoronavirus (immunology)</term><term>Coronavirus Infections (drug therapy)</term><term>Coronavirus Infections (prevention & control)</term><term>Coronavirus Infections (transmission)</term><term>Cytokine Release Syndrome (drug therapy)</term><term>Humans (MeSH)</term><term>Pandemics (prevention & control)</term><term>Pneumonia, Viral (drug therapy)</term><term>Pneumonia, Viral (prevention & control)</term><term>Pneumonia, Viral (transmission)</term><term>Quarantine (methods)</term><term>Respiratory Insufficiency (therapy)</term></keywords><keywords scheme="KwdFr" xml:lang="fr"><term>Anti-inflammatoires (usage thérapeutique)</term><term>Anticoagulants (usage thérapeutique)</term><term>Anticorps antiviraux (usage thérapeutique)</term><term>Antiviraux (usage thérapeutique)</term><term>Betacoronavirus (effets des médicaments et des substances chimiques)</term><term>Betacoronavirus (immunologie)</term><term>Humains (MeSH)</term><term>Infections à coronavirus (prévention et contrôle)</term><term>Infections à coronavirus (traitement médicamenteux)</term><term>Infections à coronavirus (transmission)</term><term>Insuffisance respiratoire (thérapie)</term><term>Pandémies (prévention et contrôle)</term><term>Pneumopathie virale (prévention et contrôle)</term><term>Pneumopathie virale (traitement médicamenteux)</term><term>Pneumopathie virale (transmission)</term><term>Quarantaine (méthodes)</term></keywords><keywords scheme="MESH" type="chemical" qualifier="therapeutic use" xml:lang="en"><term>Anti-Inflammatory Agents</term><term>Antibodies, Viral</term><term>Anticoagulants</term><term>Antiviral Agents</term></keywords><keywords scheme="MESH" qualifier="drug effects" xml:lang="en"><term>Betacoronavirus</term></keywords><keywords scheme="MESH" qualifier="drug therapy" xml:lang="en"><term>Coronavirus Infections</term><term>Cytokine Release Syndrome</term><term>Pneumonia, Viral</term></keywords><keywords scheme="MESH" qualifier="effets des médicaments et des substances chimiques" xml:lang="fr"><term>Betacoronavirus</term></keywords><keywords scheme="MESH" qualifier="immunologie" xml:lang="fr"><term>Betacoronavirus</term></keywords><keywords scheme="MESH" qualifier="immunology" xml:lang="en"><term>Betacoronavirus</term></keywords><keywords scheme="MESH" qualifier="methods" xml:lang="en"><term>Quarantine</term></keywords><keywords scheme="MESH" qualifier="méthodes" xml:lang="fr"><term>Quarantaine</term></keywords><keywords scheme="MESH" qualifier="prevention & control" xml:lang="en"><term>Coronavirus Infections</term><term>Pandemics</term><term>Pneumonia, Viral</term></keywords><keywords scheme="MESH" qualifier="prévention et contrôle" xml:lang="fr"><term>Infections à coronavirus</term><term>Pandémies</term><term>Pneumopathie virale</term></keywords><keywords scheme="MESH" qualifier="therapy" xml:lang="en"><term>Respiratory Insufficiency</term></keywords><keywords scheme="MESH" qualifier="thérapie" xml:lang="fr"><term>Insuffisance respiratoire</term></keywords><keywords scheme="MESH" qualifier="traitement médicamenteux" xml:lang="fr"><term>Infections à coronavirus</term><term>Pneumopathie virale</term></keywords><keywords scheme="MESH" qualifier="transmission" xml:lang="en"><term>Coronavirus Infections</term><term>Pneumonia, Viral</term></keywords><keywords scheme="MESH" qualifier="usage thérapeutique" xml:lang="fr"><term>Anti-inflammatoires</term><term>Anticoagulants</term><term>Anticorps antiviraux</term><term>Antiviraux</term><term>Infections à coronavirus</term><term>Pneumopathie virale</term></keywords><keywords scheme="MESH" xml:lang="en"><term>Humans</term></keywords><keywords scheme="MESH" xml:lang="fr"><term>Humains</term></keywords></textClass></profileDesc></teiHeader><front><div type="abstract" xml:lang="en">Coronavirus disease (COVID-19) is caused by severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2), which is a betacoronavirus, and is associated with cytokine storm inflammation and lung injury, leading to respiratory distress. The transmission of the virus is mediated by human contact. To control and prevent the spread of this virus, the majority of people worldwide are facing quarantine; patients are being subjected to non-specific treatments under isolation. To prevent and stop the COVID-19 pandemic, several clinical trials are in the pipeline. The current clinical trials either target the intracellular replication and spread of the virus or the cytokine storm inflammation seen in COVID-19 cases during the later stages of the disease. Since both targeting strategies are different, the window drug administration plays a crucial role in the efficacy of the treatment. Here, we review the mechanism underlying SARS-CoV-2 cell infection and potential future therapeutic approaches.</div></front></TEI><pubmed><MedlineCitation Status="MEDLINE" Owner="NLM"><PMID Version="1">32793246</PMID><DateCompleted><Year>2020</Year><Month>08</Month><Day>24</Day></DateCompleted><DateRevised><Year>2020</Year><Month>08</Month><Day>24</Day></DateRevised><Article PubModel="Electronic-eCollection"><Journal><ISSN IssnType="Electronic">1664-3224</ISSN><JournalIssue CitedMedium="Internet"><Volume>11</Volume><PubDate><Year>2020</Year></PubDate></JournalIssue><Title>Frontiers in immunology</Title><ISOAbbreviation>Front Immunol</ISOAbbreviation></Journal><ArticleTitle>Mechanisms Underlying Potential Therapeutic Approaches for COVID-19.</ArticleTitle><Pagination><MedlinePgn>1841</MedlinePgn></Pagination><ELocationID EIdType="doi" ValidYN="Y">10.3389/fimmu.2020.01841</ELocationID><Abstract><AbstractText>Coronavirus disease (COVID-19) is caused by severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2), which is a betacoronavirus, and is associated with cytokine storm inflammation and lung injury, leading to respiratory distress. The transmission of the virus is mediated by human contact. To control and prevent the spread of this virus, the majority of people worldwide are facing quarantine; patients are being subjected to non-specific treatments under isolation. To prevent and stop the COVID-19 pandemic, several clinical trials are in the pipeline. The current clinical trials either target the intracellular replication and spread of the virus or the cytokine storm inflammation seen in COVID-19 cases during the later stages of the disease. Since both targeting strategies are different, the window drug administration plays a crucial role in the efficacy of the treatment. Here, we review the mechanism underlying SARS-CoV-2 cell infection and potential future therapeutic approaches.</AbstractText><CopyrightInformation>Copyright © 2020 Benani and Ben Mkaddem.</CopyrightInformation></Abstract><AuthorList CompleteYN="Y"><Author ValidYN="Y"><LastName>Benani</LastName><ForeName>Abdelouaheb</ForeName><Initials>A</Initials><AffiliationInfo><Affiliation>Unité de Biologie Moléculaire, Institut Pasteur du Maroc, Casablanca, Morocco.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Ben Mkaddem</LastName><ForeName>Sanae</ForeName><Initials>S</Initials><AffiliationInfo><Affiliation>U978 Institut National de la Santé et de la Recherche Médicale, Bobigny, France.</Affiliation></AffiliationInfo><AffiliationInfo><Affiliation>UFR SMBH, Université Sorbonne Paris Nord, Bobigny, France.</Affiliation></AffiliationInfo></Author></AuthorList><Language>eng</Language><PublicationTypeList><PublicationType UI="D016428">Journal Article</PublicationType><PublicationType UI="D013485">Research Support, Non-U.S. Gov't</PublicationType><PublicationType UI="D016454">Review</PublicationType></PublicationTypeList><ArticleDate DateType="Electronic"><Year>2020</Year><Month>07</Month><Day>21</Day></ArticleDate></Article><MedlineJournalInfo><Country>Switzerland</Country><MedlineTA>Front Immunol</MedlineTA><NlmUniqueID>101560960</NlmUniqueID><ISSNLinking>1664-3224</ISSNLinking></MedlineJournalInfo><ChemicalList><Chemical><RegistryNumber>0</RegistryNumber><NameOfSubstance UI="D000893">Anti-Inflammatory Agents</NameOfSubstance></Chemical><Chemical><RegistryNumber>0</RegistryNumber><NameOfSubstance UI="D000914">Antibodies, Viral</NameOfSubstance></Chemical><Chemical><RegistryNumber>0</RegistryNumber><NameOfSubstance UI="D000925">Anticoagulants</NameOfSubstance></Chemical><Chemical><RegistryNumber>0</RegistryNumber><NameOfSubstance UI="D000998">Antiviral Agents</NameOfSubstance></Chemical></ChemicalList><SupplMeshList><SupplMeshName Type="Disease" UI="C000657245">COVID-19</SupplMeshName><SupplMeshName Type="Organism" UI="C000656484">severe acute respiratory syndrome coronavirus 2</SupplMeshName></SupplMeshList><CitationSubset>IM</CitationSubset><MeshHeadingList><MeshHeading><DescriptorName UI="D000893" MajorTopicYN="N">Anti-Inflammatory Agents</DescriptorName><QualifierName UI="Q000627" MajorTopicYN="N">therapeutic use</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D000914" MajorTopicYN="N">Antibodies, Viral</DescriptorName><QualifierName UI="Q000627" MajorTopicYN="N">therapeutic use</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D000925" MajorTopicYN="N">Anticoagulants</DescriptorName><QualifierName UI="Q000627" MajorTopicYN="N">therapeutic use</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D000998" MajorTopicYN="N">Antiviral Agents</DescriptorName><QualifierName UI="Q000627" MajorTopicYN="N">therapeutic use</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D000073640" MajorTopicYN="N">Betacoronavirus</DescriptorName><QualifierName UI="Q000187" MajorTopicYN="N">drug effects</QualifierName><QualifierName UI="Q000276" MajorTopicYN="N">immunology</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D018352" MajorTopicYN="N">Coronavirus Infections</DescriptorName><QualifierName UI="Q000188" MajorTopicYN="Y">drug therapy</QualifierName><QualifierName UI="Q000517" MajorTopicYN="Y">prevention & control</QualifierName><QualifierName UI="Q000635" MajorTopicYN="N">transmission</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D000080424" MajorTopicYN="N">Cytokine Release Syndrome</DescriptorName><QualifierName UI="Q000188" MajorTopicYN="Y">drug therapy</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D006801" MajorTopicYN="N">Humans</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D058873" MajorTopicYN="N">Pandemics</DescriptorName><QualifierName UI="Q000517" MajorTopicYN="Y">prevention & control</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D011024" MajorTopicYN="N">Pneumonia, Viral</DescriptorName><QualifierName UI="Q000188" MajorTopicYN="Y">drug therapy</QualifierName><QualifierName UI="Q000517" MajorTopicYN="Y">prevention & control</QualifierName><QualifierName UI="Q000635" MajorTopicYN="N">transmission</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D011790" MajorTopicYN="N">Quarantine</DescriptorName><QualifierName UI="Q000379" MajorTopicYN="N">methods</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D012131" MajorTopicYN="N">Respiratory Insufficiency</DescriptorName><QualifierName UI="Q000628" MajorTopicYN="Y">therapy</QualifierName></MeshHeading></MeshHeadingList><KeywordList Owner="NOTNLM"><Keyword MajorTopicYN="Y">COVID-19</Keyword><Keyword MajorTopicYN="Y">SARS-CoV-2</Keyword><Keyword MajorTopicYN="Y">cytokine treatment</Keyword><Keyword MajorTopicYN="Y">immune therapy</Keyword><Keyword MajorTopicYN="Y">monoclonal antibody</Keyword><Keyword MajorTopicYN="Y">respiratory distress</Keyword></KeywordList></MedlineCitation><PubmedData><History><PubMedPubDate PubStatus="received"><Year>2020</Year><Month>04</Month><Day>24</Day></PubMedPubDate><PubMedPubDate PubStatus="accepted"><Year>2020</Year><Month>07</Month><Day>08</Day></PubMedPubDate><PubMedPubDate PubStatus="entrez"><Year>2020</Year><Month>8</Month><Day>15</Day><Hour>6</Hour><Minute>0</Minute></PubMedPubDate><PubMedPubDate PubStatus="pubmed"><Year>2020</Year><Month>8</Month><Day>15</Day><Hour>6</Hour><Minute>0</Minute></PubMedPubDate><PubMedPubDate PubStatus="medline"><Year>2020</Year><Month>8</Month><Day>25</Day><Hour>6</Hour><Minute>0</Minute></PubMedPubDate></History><PublicationStatus>epublish</PublicationStatus><ArticleIdList><ArticleId IdType="pubmed">32793246</ArticleId><ArticleId IdType="doi">10.3389/fimmu.2020.01841</ArticleId><ArticleId IdType="pmc">PMC7385230</ArticleId></ArticleIdList><ReferenceList><Reference><Citation>Lancet. 2020 Feb 15;395(10223):514-523</Citation><ArticleIdList><ArticleId IdType="pubmed">31986261</ArticleId></ArticleIdList></Reference><Reference><Citation>Pharmaceut Med. 2020 Aug;34(4):223-231</Citation><ArticleIdList><ArticleId IdType="pubmed">32535732</ArticleId></ArticleIdList></Reference><Reference><Citation>Emerg Infect Dis. 2005 Mar;11(3):417-24</Citation><ArticleIdList><ArticleId IdType="pubmed">15757557</ArticleId></ArticleIdList></Reference><Reference><Citation>Eur J Pharmacol. 2009 Dec 25;625(1-3):220-33</Citation><ArticleIdList><ArticleId IdType="pubmed">19836374</ArticleId></ArticleIdList></Reference><Reference><Citation>Lancet. 2020 Feb 15;395(10223):473-475</Citation><ArticleIdList><ArticleId IdType="pubmed">32043983</ArticleId></ArticleIdList></Reference><Reference><Citation>Viral Immunol. 2019 Jul/Aug;32(6):244-251</Citation><ArticleIdList><ArticleId IdType="pubmed">31188076</ArticleId></ArticleIdList></Reference><Reference><Citation>Int J Antimicrob Agents. 2020 Jul;56(1):105949</Citation><ArticleIdList><ArticleId IdType="pubmed">32205204</ArticleId></ArticleIdList></Reference><Reference><Citation>Lancet. 2004 Jun 26;363(9427):2139-41</Citation><ArticleIdList><ArticleId IdType="pubmed">15220038</ArticleId></ArticleIdList></Reference><Reference><Citation>Annu Rev Med. 2017 Jan 14;68:387-399</Citation><ArticleIdList><ArticleId IdType="pubmed">27576010</ArticleId></ArticleIdList></Reference><Reference><Citation>JAMA. 2003 Jun 4;289(21):2801-9</Citation><ArticleIdList><ArticleId IdType="pubmed">12734147</ArticleId></ArticleIdList></Reference><Reference><Citation>Nat Immunol. 2006 Mar;7(3):311-7</Citation><ArticleIdList><ArticleId IdType="pubmed">16462739</ArticleId></ArticleIdList></Reference><Reference><Citation>J Virol. 2006 Jan;80(2):941-50</Citation><ArticleIdList><ArticleId IdType="pubmed">16378996</ArticleId></ArticleIdList></Reference><Reference><Citation>Thromb Haemost. 2020 Jun;120(6):998-1000</Citation><ArticleIdList><ArticleId IdType="pubmed">32316063</ArticleId></ArticleIdList></Reference><Reference><Citation>Clin Immunol. 2014 Dec;155(2):213-9</Citation><ArticleIdList><ArticleId IdType="pubmed">25451159</ArticleId></ArticleIdList></Reference><Reference><Citation>MAbs. 2010 Jan-Feb;2(1):53-66</Citation><ArticleIdList><ArticleId IdType="pubmed">20168090</ArticleId></ArticleIdList></Reference><Reference><Citation>J Am Acad Dermatol. 1988 Jun;18(6):1246-52</Citation><ArticleIdList><ArticleId IdType="pubmed">3385039</ArticleId></ArticleIdList></Reference><Reference><Citation>Zhejiang Da Xue Xue Bao Yi Xue Ban. 2020 May 25;49(2):215-219</Citation><ArticleIdList><ArticleId IdType="pubmed">32391667</ArticleId></ArticleIdList></Reference><Reference><Citation>Science. 2003 Oct 10;302(5643):276-8</Citation><ArticleIdList><ArticleId IdType="pubmed">12958366</ArticleId></ArticleIdList></Reference><Reference><Citation>Autophagy. 2013 Jul;9(7):1119-20</Citation><ArticleIdList><ArticleId IdType="pubmed">23670050</ArticleId></ArticleIdList></Reference><Reference><Citation>Cell Res. 2020 Mar;30(3):269-271</Citation><ArticleIdList><ArticleId IdType="pubmed">32020029</ArticleId></ArticleIdList></Reference><Reference><Citation>Eur J Clin Microbiol Infect Dis. 2020 Jul;39(7):1209-1220</Citation><ArticleIdList><ArticleId IdType="pubmed">32328850</ArticleId></ArticleIdList></Reference><Reference><Citation>Clin Infect Dis. 2020 Jul 28;71(15):732-739</Citation><ArticleIdList><ArticleId IdType="pubmed">32150618</ArticleId></ArticleIdList></Reference><Reference><Citation>Cell Mol Life Sci. 2007 Aug;64(15):2006-12</Citation><ArticleIdList><ArticleId IdType="pubmed">17558469</ArticleId></ArticleIdList></Reference><Reference><Citation>Sci Transl Med. 2017 Jun 28;9(396):</Citation><ArticleIdList><ArticleId IdType="pubmed">28659436</ArticleId></ArticleIdList></Reference><Reference><Citation>Asian Pac J Allergy Immunol. 2020 Mar;38(1):10-18</Citation><ArticleIdList><ArticleId IdType="pubmed">32134278</ArticleId></ArticleIdList></Reference><Reference><Citation>Methods Enzymol. 1995;248:283-305</Citation><ArticleIdList><ArticleId IdType="pubmed">7674927</ArticleId></ArticleIdList></Reference><Reference><Citation>J Virol. 2005 Feb;79(3):1635-44</Citation><ArticleIdList><ArticleId IdType="pubmed">15650189</ArticleId></ArticleIdList></Reference><Reference><Citation>Adv Exp Med Biol. 1980;130:1-27</Citation><ArticleIdList><ArticleId IdType="pubmed">6250339</ArticleId></ArticleIdList></Reference><Reference><Citation>Clin Infect Dis. 2020 Apr 27;:</Citation><ArticleIdList><ArticleId IdType="pubmed">32338708</ArticleId></ArticleIdList></Reference><Reference><Citation>Curr Pharmacol Rep. 2020 May 11;:1-15</Citation><ArticleIdList><ArticleId IdType="pubmed">32395418</ArticleId></ArticleIdList></Reference><Reference><Citation>Lancet. 2020 May 2;395(10234):1407-1409</Citation><ArticleIdList><ArticleId IdType="pubmed">32278362</ArticleId></ArticleIdList></Reference><Reference><Citation>Crit Care Med. 2020 May 27;:</Citation><ArticleIdList><ArticleId IdType="pubmed">32467443</ArticleId></ArticleIdList></Reference><Reference><Citation>Parasitol Res. 2012 Jul;111(1):1-6</Citation><ArticleIdList><ArticleId IdType="pubmed">22411634</ArticleId></ArticleIdList></Reference><Reference><Citation>J Cardiovasc Pharmacol. 2002 Apr;39(4):478-87</Citation><ArticleIdList><ArticleId IdType="pubmed">11904521</ArticleId></ArticleIdList></Reference><Reference><Citation>J Immunol. 2011 Apr 15;186(8):4794-804</Citation><ArticleIdList><ArticleId IdType="pubmed">21398612</ArticleId></ArticleIdList></Reference><Reference><Citation>Immunotherapy. 2016 Jul;8(8):959-70</Citation><ArticleIdList><ArticleId IdType="pubmed">27381687</ArticleId></ArticleIdList></Reference><Reference><Citation>Clinics (Sao Paulo). 2013 Jun;68(6):766-71</Citation><ArticleIdList><ArticleId IdType="pubmed">23778483</ArticleId></ArticleIdList></Reference><Reference><Citation>J Korean Med Sci. 2020 Feb 17;35(6):e79</Citation><ArticleIdList><ArticleId IdType="pubmed">32056407</ArticleId></ArticleIdList></Reference><Reference><Citation>Platelets. 2020 May 18;31(4):490-496</Citation><ArticleIdList><ArticleId IdType="pubmed">32297540</ArticleId></ArticleIdList></Reference><Reference><Citation>J Virol. 2020 Mar 17;94(7):</Citation><ArticleIdList><ArticleId IdType="pubmed">31996437</ArticleId></ArticleIdList></Reference><Reference><Citation>PLoS Med. 2006 Jul;3(7):e237</Citation><ArticleIdList><ArticleId IdType="pubmed">16796401</ArticleId></ArticleIdList></Reference><Reference><Citation>J Pharm Biomed Anal. 2017 Oct 25;145:248-254</Citation><ArticleIdList><ArticleId IdType="pubmed">28668653</ArticleId></ArticleIdList></Reference><Reference><Citation>Ann Oncol. 2020 Jul;31(7):961-964</Citation><ArticleIdList><ArticleId IdType="pubmed">32247642</ArticleId></ArticleIdList></Reference><Reference><Citation>Cell. 2010 Feb 5;140(3):313-26</Citation><ArticleIdList><ArticleId IdType="pubmed">20144757</ArticleId></ArticleIdList></Reference><Reference><Citation>JAMA Ophthalmol. 2014 Dec;132(12):1453-60</Citation><ArticleIdList><ArticleId IdType="pubmed">25275721</ArticleId></ArticleIdList></Reference><Reference><Citation>Nat Rev Drug Discov. 2020 Mar;19(3):149-150</Citation><ArticleIdList><ArticleId IdType="pubmed">32127666</ArticleId></ArticleIdList></Reference><Reference><Citation>mBio. 2018 Mar 6;9(2):</Citation><ArticleIdList><ArticleId IdType="pubmed">29511076</ArticleId></ArticleIdList></Reference><Reference><Citation>J Natl Cancer Inst. 1983 Nov;71(5):1053-7</Citation><ArticleIdList><ArticleId IdType="pubmed">6580482</ArticleId></ArticleIdList></Reference><Reference><Citation>Antimicrob Agents Chemother. 2016 Oct 21;60(11):6532-6539</Citation><ArticleIdList><ArticleId IdType="pubmed">27550352</ArticleId></ArticleIdList></Reference><Reference><Citation>J Virol. 2009 Apr;83(8):3528-39</Citation><ArticleIdList><ArticleId IdType="pubmed">19193795</ArticleId></ArticleIdList></Reference><Reference><Citation>J Virol. 2010 Dec;84(24):12658-64</Citation><ArticleIdList><ArticleId IdType="pubmed">20926566</ArticleId></ArticleIdList></Reference><Reference><Citation>J Gastroenterol. 2010 Mar;45(3):335-41</Citation><ArticleIdList><ArticleId IdType="pubmed">19876587</ArticleId></ArticleIdList></Reference><Reference><Citation>J Clin Invest. 2020 May 1;130(5):2202-2205</Citation><ArticleIdList><ArticleId IdType="pubmed">32217834</ArticleId></ArticleIdList></Reference><Reference><Citation>J Biol Regul Homeost Agents. 2020 Mar 14;34(2):327-331</Citation><ArticleIdList><ArticleId IdType="pubmed">32171193</ArticleId></ArticleIdList></Reference><Reference><Citation>PLoS One. 2014 Jul 14;9(7):e102415</Citation><ArticleIdList><ArticleId IdType="pubmed">25019613</ArticleId></ArticleIdList></Reference><Reference><Citation>BMC Musculoskelet Disord. 2019 Jun 15;20(1):286</Citation><ArticleIdList><ArticleId IdType="pubmed">31200688</ArticleId></ArticleIdList></Reference><Reference><Citation>Med Mal Infect. 2020 Jun;50(4):384</Citation><ArticleIdList><ArticleId IdType="pubmed">32240719</ArticleId></ArticleIdList></Reference><Reference><Citation>Trials. 2020 May 24;21(1):422</Citation><ArticleIdList><ArticleId IdType="pubmed">32448345</ArticleId></ArticleIdList></Reference><Reference><Citation>Virol J. 2005 Aug 22;2:69</Citation><ArticleIdList><ArticleId IdType="pubmed">16115318</ArticleId></ArticleIdList></Reference><Reference><Citation>Nature. 2016 Mar 17;531(7594):381-5</Citation><ArticleIdList><ArticleId IdType="pubmed">26934220</ArticleId></ArticleIdList></Reference><Reference><Citation>Jpn J Pharmacol. 1986 Jun;41(2):155-62</Citation><ArticleIdList><ArticleId IdType="pubmed">2427760</ArticleId></ArticleIdList></Reference><Reference><Citation>J Virol. 2011 Jan;85(2):873-82</Citation><ArticleIdList><ArticleId IdType="pubmed">21068237</ArticleId></ArticleIdList></Reference><Reference><Citation>Biochem Biophys Res Commun. 2005 Jan 28;326(4):905-8</Citation><ArticleIdList><ArticleId IdType="pubmed">15607755</ArticleId></ArticleIdList></Reference><Reference><Citation>Drug Saf. 2020 Jul;43(7):645-656</Citation><ArticleIdList><ArticleId IdType="pubmed">32468196</ArticleId></ArticleIdList></Reference><Reference><Citation>J Rheumatol. 1997 Jan;24(1):55-60</Citation><ArticleIdList><ArticleId IdType="pubmed">9002011</ArticleId></ArticleIdList></Reference><Reference><Citation>Lancet. 2020 Feb 15;395(10223):497-506</Citation><ArticleIdList><ArticleId IdType="pubmed">31986264</ArticleId></ArticleIdList></Reference><Reference><Citation>Science. 2005 Sep 16;309(5742):1864-8</Citation><ArticleIdList><ArticleId IdType="pubmed">16166518</ArticleId></ArticleIdList></Reference><Reference><Citation>Front Immunol. 2020 May 01;11:827</Citation><ArticleIdList><ArticleId IdType="pubmed">32425950</ArticleId></ArticleIdList></Reference><Reference><Citation>Internist (Berl). 2019 Nov;60(11):1136-1145</Citation><ArticleIdList><ArticleId IdType="pubmed">31455974</ArticleId></ArticleIdList></Reference><Reference><Citation>Front Microbiol. 2019 May 10;10:1057</Citation><ArticleIdList><ArticleId IdType="pubmed">31134045</ArticleId></ArticleIdList></Reference><Reference><Citation>J Virol. 2005 May;79(10):5900-6</Citation><ArticleIdList><ArticleId IdType="pubmed">15857975</ArticleId></ArticleIdList></Reference><Reference><Citation>J Int Med Res. 2018 Jun;46(6):2410-2422</Citation><ArticleIdList><ArticleId IdType="pubmed">29644918</ArticleId></ArticleIdList></Reference><Reference><Citation>J Virol. 2016 Jan 06;90(6):3086-92</Citation><ArticleIdList><ArticleId IdType="pubmed">26739045</ArticleId></ArticleIdList></Reference><Reference><Citation>Sci Transl Med. 2019 Jul 10;11(500):</Citation><ArticleIdList><ArticleId IdType="pubmed">31292264</ArticleId></ArticleIdList></Reference><Reference><Citation>Lancet. 2020 Feb 15;395(10223):507-513</Citation><ArticleIdList><ArticleId IdType="pubmed">32007143</ArticleId></ArticleIdList></Reference><Reference><Citation>Cell. 2020 Apr 16;181(2):271-280.e8</Citation><ArticleIdList><ArticleId IdType="pubmed">32142651</ArticleId></ArticleIdList></Reference><Reference><Citation>J Med Virol. 2020 Apr 8;:</Citation><ArticleIdList><ArticleId IdType="pubmed">32266995</ArticleId></ArticleIdList></Reference><Reference><Citation>Int J Antimicrob Agents. 2020 Apr;55(4):105933</Citation><ArticleIdList><ArticleId IdType="pubmed">32147516</ArticleId></ArticleIdList></Reference><Reference><Citation>Blood Rev. 2020 May 15;:100707</Citation><ArticleIdList><ArticleId IdType="pubmed">32425294</ArticleId></ArticleIdList></Reference><Reference><Citation>Lancet Infect Dis. 2006 Feb;6(2):67-9</Citation><ArticleIdList><ArticleId IdType="pubmed">16439323</ArticleId></ArticleIdList></Reference><Reference><Citation>J Clin Virol. 2004 Sep;31(1):69-75</Citation><ArticleIdList><ArticleId IdType="pubmed">15288617</ArticleId></ArticleIdList></Reference></ReferenceList></PubmedData></pubmed><affiliations><list><country><li>France</li><li>Maroc</li></country><region><li>Île-de-France</li></region><settlement><li>Bobigny</li></settlement></list><tree><country name="Maroc"><noRegion><name sortKey="Benani, Abdelouaheb" sort="Benani, Abdelouaheb" uniqKey="Benani A" first="Abdelouaheb" last="Benani">Abdelouaheb Benani</name></noRegion></country><country name="France"><region name="Île-de-France"><name sortKey="Ben Mkaddem, Sanae" sort="Ben Mkaddem, Sanae" uniqKey="Ben Mkaddem S" first="Sanae" last="Ben Mkaddem">Sanae Ben Mkaddem</name></region><name sortKey="Ben Mkaddem, Sanae" sort="Ben Mkaddem, Sanae" uniqKey="Ben Mkaddem S" first="Sanae" last="Ben Mkaddem">Sanae Ben Mkaddem</name></country></tree></affiliations></record>Pour manipuler ce document sous Unix (Dilib)
EXPLOR_STEP=$WICRI_ROOT/Sante/explor/CovidFranceV1/Data/Main/Exploration
HfdSelect -h $EXPLOR_STEP/biblio.hfd -nk 000B26 | SxmlIndent | more
Ou
HfdSelect -h $EXPLOR_AREA/Data/Main/Exploration/biblio.hfd -nk 000B26 | SxmlIndent | more
Pour mettre un lien sur cette page dans le réseau Wicri
{{Explor lien
|wiki= Sante
|area= CovidFranceV1
|flux= Main
|étape= Exploration
|type= RBID
|clé= pubmed:32793246
|texte= Mechanisms Underlying Potential Therapeutic Approaches for COVID-19.
}}
Pour générer des pages wiki
HfdIndexSelect -h $EXPLOR_AREA/Data/Main/Exploration/RBID.i -Sk "pubmed:32793246" \
| HfdSelect -Kh $EXPLOR_AREA/Data/Main/Exploration/biblio.hfd \
| NlmPubMed2Wicri -a CovidFranceV1
| This area was generated with Dilib version V0.6.37. |  |